QIA56
MMP-9 ELISA Kit
Gelatinase B ELISA Kit, 92 kDa Gelatinase ELISA Kit, Matrix Metalloproteinase 9 ELISA Kit
ご質問については、カスタマーサービスまでご連絡ください。
メルク株式会社
目黒区下目黒1-8-1
153-8927 東京
Japan
TEL： 0120-189-390
Fax: 0120-189-350
E-mail mj_service@merckgroup.com
31 5月 2012
ローディング
A non-isotopic, sandwich ELISA for the in vitro measurement of human MMP-9 in tissue culture supernatant, serum, or plasma.
| 製品情報 | |||
|---|---|---|---|
| Format | 96-well plate | ||
| Form | 34 or 41 Tests | ||
| Detection method | Colorimetric | ||
| Species reactivity | human | ||
| Avoid freeze/thaw | はい | ||
| Specificity | Human pro-MMP-9 protein and MMP-9/TIMP-1 complex | ||
| Sensitivity | 0.1 ng/ml | ||
| Assay range | 0.625 - 20 ng/ml | ||
| Assay time | 3.5 h | ||
| Sample type | Tissue culture media, serum, plasma | ||
| Kit contains | 96-Well Coated Plate, MMP-9 Standard, Biotinylated Detector Antibody, 400X Streptavidin Peroxidase Conjugate, Diluent, Substrate, Assay Buffers, Stop Solution, Plate Sealer, and a user protocol. | ||
| Declaration | Not available for sale in Japan. | ||
| 保管と送付情報 | |||
|---|---|---|---|
|
危険物に関する注意： 今回の納品における危険物の特性により、追加の送料が適用される場合があります。サイズによって危険物にかかる追加送料が免除されることもあります。送料に関する詳細はオーダーマネージメントまでお問い合わせください。 |
|||
| Storage | -20°C | ||
| Ship |
Dry Ice Only
Multiple Toxicity Values, refer to MSDS |
||
| 安全性情報 | |||
|---|---|---|---|
| S フレーズ |
S: 26-36/37/39-45 |
||
| R フレーズ |
R: 23/24/25-35-36-40-43 |
||
| データ | |||
|---|---|---|---|
 The mean signal of each standard run in replicates of four in eight assays using two different lots of plates and two different lots of detector antibody.   The pooled coefficients of variation (according to the formula of Henry et. al., 1974) and between assay coefficients of variation are plotted against MMP-9 concentrations. The pooled data were collected from samples run eight times using two different lots of plates and two different lots of detector antibody in replicates of four on two separate occasions.  The study tested dilution-recovery of ten positive samples. The dilutions were run in the MMP-9 ELISA Kit and the "found" doses were plotted against the "expected" doses to determine linearity of dilution. The slope is not significantly different from one and the intercept is not significantly different from zero. These studies are consistent with the absence of cross-reacting and matrix effects such as pH, salts, and endogenous binders that interfere with the reagents used in the assay. <b>Note:</b> Ca = Cancer; NHS = Normal Human Sera; NHP = Normal Human Plasma; PMA = Phorbol 12-myristate 13-acetate; EGF = Epidermal Growth Factor; AR = Amphiregulin; Both = EGF and AR; A = 2 x 10<sup>6</sup> cells/ml; B = 1.0 x 10<sup>6</sup> cells/ml.  Levels of MMP-9 detected by the ELISA after immunoaffinity extraction of MMP-9 positive samples (PMA treated HT1080 and HL-60 cells) with a MMP-9 antibody that is not used in the ELISA, a TIMP-1 antibody, a TIMP-2 antibody and a TIMP-3 antibody.  APMA promotes the autocatalytic cleavage of the N-terminal propeptide of the latent 92-kDa enzyme to yield the active form of the enzyme. Analysis of the samples by zymography showed both cleavage of the proenzyme by APMA and a good correlation with the levels of the proenzyme determined with the MMP-9 ELISA. Several methods of MMP-9 induction were used to generate positive samples such as treatment with 50 ng/ml amphiregulin (AR), 50 ng/ml epidermal growth factor (EGF), 1 ng/ml transforming growth factor β (TGFβ) and 25 ng/ml phorbol 12-myristate 13-acetate (PMA). Normal human sera (NHS) containing moderate levels of MMP-9 were treated with APMA and analyzed. |
